These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 7703566

  • 1. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
    Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J.
    Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
    [Abstract] [Full Text] [Related]

  • 2. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.
    Cancer Res; 1993 Jun 01; 53(11):2513-21. PubMed ID: 8388317
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
    Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J.
    Br J Cancer; 1994 Feb 01; 69(2):398-405. PubMed ID: 8297742
    [Abstract] [Full Text] [Related]

  • 4. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
    de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, van Putten WL, Benraad TJ, Foekens JA.
    Br J Cancer; 1999 Mar 01; 79(7-8):1190-8. PubMed ID: 10098758
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, Dano K, Klijn JG, Brünner N, Foekens JA.
    Clin Cancer Res; 1995 Oct 01; 1(10):1079-87. PubMed ID: 9815897
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 01; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 13. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
    Pedersen AN, Christensen IJ, Stephens RW, Briand P, Mouridsen HT, Danø K, Brünner N.
    Cancer Res; 2000 Dec 15; 60(24):6927-34. PubMed ID: 11156392
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
    Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG.
    Cancer Res; 1992 Nov 01; 52(21):6101-5. PubMed ID: 1394237
    [Abstract] [Full Text] [Related]

  • 15. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS.
    Cancer; 1997 Mar 01; 79(5):878-83. PubMed ID: 9041148
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.
    Thromb Haemost; 2004 Mar 01; 91(3):450-6. PubMed ID: 14983219
    [Abstract] [Full Text] [Related]

  • 19. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM, Han DM, Yu ZK, Fan EZ, Li Y.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb 01; 38(1):39-42. PubMed ID: 12778766
    [Abstract] [Full Text] [Related]

  • 20. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V.
    Int J Mol Med; 2008 Feb 01; 21(2):251-9. PubMed ID: 18204793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.